Companies / BOC Sciences / reslizumab
BOC Sciences

reslizumab | BOC Sciences

Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.